Nanovector-based prolyl hydroxylase domain 2 silencing system enhances the efficiency of stem cell transplantation for infarcted myocardium repair
Kai Zhu,1,2 Hao Lai,1,2 Changfa Guo,1,2 Jun Li,1,2 Yulin Wang,1,2 Lingyan Wang,3 Chunsheng Wang1,2 1Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China; 2Shanghai Institute of Cardiovascular Disease, Shanghai, People’s Repub...
Guardado en:
Autores principales: | Zhu K, Lai H, Guo C, Li J, Wang Y, Wang L, Wang C |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/58d4768287014930b8f4c95bde483249 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases
por: Rasheduzzaman Chowdhury, et al.
Publicado: (2016) -
Use of cyclic peptides to induce crystallization: case study with prolyl hydroxylase domain 2
por: Rasheduzzaman Chowdhury, et al.
Publicado: (2020) -
Effect of proline analogues on activity of human prolyl hydroxylase and the regulation of HIF signal transduction pathway.
por: Xiaoyan Ma, et al.
Publicado: (2014) -
Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.
por: Francesca Spinella, et al.
Publicado: (2010) -
Loss of Endothelial Hypoxia Inducible Factor‐Prolyl Hydroxylase 2 Induces Cardiac Hypertrophy and Fibrosis
por: Zhiyu Dai, et al.
Publicado: (2021)